ERBB2 and breast cancer: In this study, we assessed the evolution of HER2 expression from puncture biopsy to residual disease after NAC, and the overall rate of HER2-evolution after NAC was 19.7%, which resulted in a lower figure than in other studies because only BC patients who were HER2-negative both before and after NAC were included in this study.